Madrigal Pharmaceuticals
$499.40Change from previous close: −0.06%Absolute change: −$0.31
At a glance
- Revenue growth
- +432.05%
- 2025 vs 2024
- Net margin
- -30.1%
- 2024: -258.6%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total revenue | 958 | 180 | 0.0 | 0.0 | — |
| Cost of revenue | 56.1 | 6.2 | 0.0 | 0.0 | — |
| Gross profit | 902 | 174 | 0.0 | 0.0 | — |
| Selling, general and administrative | 814 | 435 | 108 | 48.1 | — |
| Research and development | 389 | 237 | 272 | 245 | — |
| Operating income | -300 | -498 | -380 | -294 | — |
| EBIT | -266 | -451 | -361 | -291 | — |
| EBITDA | -264 | -450 | -360 | -291 | — |
| Interest expense | 22.3 | 14.7 | 12.7 | 4.0 | — |
| Pre-tax income | -288 | -466 | -374 | -295 | — |
| Net income | -288 | -466 | -374 | -295 | — |
| Net income to common shareholders | -288 | -466 | -374 | -295 | — |
| Basic EPS | -12.85 | -21.90 | -19.99 | -17.23 | — |
| Diluted EPS | -12.85 | -21.90 | -19.99 | -17.23 | — |
| Average shares (basic) | 22.4 | 21.3 | 18.7 | 17.1 | — |
| Average shares (diluted) | 22.4 | 21.3 | 18.7 | 17.1 | — |